INS and Parkinson disease: It is now known that while TZDs vary dramatically in their ability to directly activate PPARγ they can all attenuate the transport of pyruvate through MPC [55, 56]. The protoype MPC-targeting drug MSDC-0160 not only improves insulin-sensitivity, but has also is beneficial is several cell and animal models of PD (discussed below).